[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"laryngeal-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:laryngeal-carcinoma":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,45,73,103,142,167],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100617607","quality-of-life-and-functional-outcomes-in-laryngeal-cancer-patients-100617607",false,"NCT07320820","Quality of Life and Functional Outcomes in Laryngeal Cancer Patients","Assessment of Quality of Life, Patient Satisfaction, Swallowing Function, Voice Outcomes, Pain, and Anxiety-Depression at Baseline and at 3-, 6-, and 12-Month Follow-Up in Patients Diagnosed With Laryngeal Squamous Cell Carcinoma: A Prospective Questionnaire-Based Study","QoL in LSSC","Inclusion Criteria:\n\n* Age ≥ 18 years at the time of enrollment.\n* Histopathologically confirmed diagnosis of laryngeal squamous cell carcinoma.\n* Planned to undergo surgical treatment or radiotherapy\u002Fchemoradiotherapy as part of standard oncological care.\n* Willing and able to participate in the study and to provide written informed consent.\n* No history of psychiatric or neurological disorders that could impair comprehension, questionnaire completion, or study participation.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years.\n* Presence of comorbid conditions that may independently affect swallowing or voice functions.\n* Patients who withdraw consent or request to discontinue participation during or after the treatment period.\n* History of psychiatric disorders or use of psychiatric medications that may interfere with study participation or completion of patient-reported outcome measures.","ALL","18 Years",{"count":20,"type":21},120,"ESTIMATED","12 Months","OBSERVATIONAL","Laryngeal squamous cell carcinomas are head and neck malignancies that directly affect both swallowing and voice functions and are associated with a significant deterioration in patients' quality of life throughout the treatment process.\n\nThe aim of this study is to evaluate quality of life, voice and swallowing functions, pain, anxiety-depression levels, and patient satisfaction at the pre-treatment period and at the 3rd, 6th, and 12th months post-treatment in patients with laryngeal malignancies, using validated questionnaires, in order to:\n\nElucidate the course of functional recovery following treatment,\n\nIndividualize rehabilitation and follow-up strategies, and\n\nExamine the relationship between functional outcomes and oncological survival.",[26,27,28,29,30,31,32],"Laryngeal Carcinoma","Quality of Life (QOL)","Patient Satisfaction","Voice Quality","Swallowing Function","Pain Management","Anxiety Depression","NOT_YET_RECRUITING","2026-04-21",{"date":36,"type":37},"2026-04-22","ACTUAL",{"date":39,"type":21},"2026-04-02",{"date":41,"type":21},"2027-12-31",{"name":43,"class":44},"Saglik Bilimleri Universitesi","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100522275","phase-ii-randomized-study-of-hypofractionated-versus-conventional-radiotherapy-100522275","NCT06080503","Phase II Randomized Study of Hypofractionated Versus Conventional Radiotherapy","G-FORCE: Phase II Randomized Study of Glottic Larynx Hypofractionated Radiotherapy Versus ConvEntional Radiotherapy","G-FORCE","Inclusion Criteria:\n\n1. Pathologically-proven diagnosis of squamous cell carcinoma in situ, squamous cell carcinoma, or squamous cell variants (sarcomatoid, verrucous, basaloid, and papillary subtypes) involving the glottic larynx.\n2. Clinical stage 0-II (AJCC, 8th edition) with direct laryngoscopy showing no evidence of greater than stage II true glottic larynx cancer and PET\u002FCT or CT neck showing no evidence of regional disease.\n3. Minimum age is 18 years.\n4. ECOG Performance Status 0-2\n5. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.\n\n   5.1 A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:\n   * Has not undergone a hysterectomy or bilateral oophorectomy; or\n   * Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).\n6. Ability to understand and the willingness to sign a written informed consent.\n\nExclusion Criteria:\n\n1. AJCC stage III or stage IV larynx cancer\n2. Involvement of the arytenoid cartilage beyond the vocal process.\n3. Prior chemotherapy for treatment of the targeted larynx lesion.\n4. Synchronous primaries in the head and neck\n5. Prior radiotherapy to the region of the study cancer that would result in overlap of radiation fields.\n6. Subjects smoking in excess of 1 pack of cigarettes per day.\n7. Subjects may not be receiving any other investigational agents.\n8. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.",{"count":54,"type":21},67,"INTERVENTIONAL",[57],"NA","To compare the acute tolerance of highly conformal hypofractionated versus conventional radiotherapy.",[26],[61],"Larynx","RECRUITING","2025-11-24",{"date":65,"type":37},"2025-11-26",{"date":67,"type":37},"2024-03-14",{"date":69,"type":21},"2029-03-14",{"name":71,"class":44},"University of Texas Southwestern Medical Center",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":55,"phases":83,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":72},"100588369","telemedicine-follow-up-for-early-laryngeal-cancer-a-randomized-controlled-trial-comparing-care-close-to-home-versus-standard-of-care-100588369","NCT06940505","Telemedicine Follow-Up for Early Laryngeal Cancer: a Randomized Controlled Trial Comparing Care Close to Home Versus Standard of Care","Telemedicine Follow-up for Pre-malignant and Malignant Glottic Lesions: a Randomised Controlled Trial Study Protocol Comparing Care Close to Home Versus Standard of Care","Telemedicine","Inclusion Criteria:\n\n* patients who underwent TOLS for early stage glottic squamous cell carcinoma (T1 or carcinoma-in-situ)\n* a one-way travel time to the HNOC of ≥45 minutes (intervention group) or \\\u003C 30 minutes (control group)\n* within 2 years postoperatively\n* can speak and write Dutch\n\nExclusion Criteria:\n\n* Patients will be excluded if they continue to undergo follow-up for other (head and neck) cancers in the HNOC.",{"count":82,"type":21},140,[57],"The goal of this clinical trial is to evaluate whether Telemedicine follow-up is a satisfactory and safe alternative to traditional follow-up care for patients treated for early glottic (vocal cord) cancer, particularly those who live far from a specialized head and neck oncology centre (HNOC).\n\nThe main questions it aims to answer are:\n\nIs patient satisfaction with Telemedicine follow-up comparable to standard care?\n\nIs the safety of Telemedicine follow-up (measured by recurrence rates, complications, and survival) comparable to in-person follow-up at an HNOC?\n\nResearchers will compare patients receiving Telemedicine follow-up in a nearby hospital with standard in-person follow-up at the HNOC, to see if remote evaluation of endoscopic procedures can maintain patient satisfaction and safety outcomes.\n\nParticipants with a travel time of \\> 45 minutes from a HNOC will:\n\nBe randomly assigned to either a Telemedicine follow-up group (in a nearby hospital, by a general ENT-surgeon) or a standard of care group\n\nUndergo follow-up including HD-laryngoscopy, according to clinical guidelines\n\nHave endoscopy videos evaluated remotely by specialists at the HNOC (= Telemedicine) (intervention group only)\n\nComplete surveys including patient-reported outcomes and experience measures at baseline, 6 months, and 12 months",[86,26],"Head and Neck Cancers",[88,89,90,91,92,93],"head and neck cancer","follow-up","patient satisfaction","telemedicine","patient reported outcome measures","quality of life","2025-08-13",{"date":96,"type":37},"2025-08-19",{"date":98,"type":37},"2025-04-01",{"date":100,"type":21},"2027-06-01",{"name":102,"class":44},"University Medical Center Groningen",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":55,"phases":113,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":72},"100589709","phase-3-comparing-neoadjuvant-chemotherapy-combined-with-pd-1-inhibitor-versus-neoadjuvant-chemotherapy-in-locally-advanced-laryngeal-and-hypopharyngeal-carcinoma-100589709","NCT06957938","Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Carcinoma","A Prospective, Multi-centered, Randomized Phase III Study to Compare Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Carcinoma","Inclusion Criteria:\n\n1. Patients who have signed the informed consent form and are willing to complete the study according to the protocol.\n2. Age ≥18 years and ≤75 years.\n3. Histologically confirmed squamous cell carcinoma of the larynx or hypopharynx.\n4. Locally advanced laryngeal or hypopharyngeal cancer that requires total laryngectomy and is amenable to total laryngectomy according to surgical assessment.\n5. At least one measurable lesion before treatment, which meets the criteria for \"measurable lesion\" according to RECIST 1.1 criteria.\n6. An expected survival of \\>3 months.\n7. ECOG performance status of 0-1.\n8. Adequate organ function, meeting the following requirements:\n\n   1. Absolute neutrophil count (ANC) ≥1.5×10\\^9\u002FL;\n   2. Platelet count ≥100×10\\^9\u002FL;\n   3. Hemoglobin ≥9 g\u002FdL;\n   4. Serum albumin ≥2.8 g\u002FdL;\n   5. Total bilirubin ≤1.5×ULN, ALT, AST, and\u002For ALP ≤3×ULN;\n   6. Serum creatinine ≤1.5×ULN and creatinine clearance ≥60 mL\u002Fmin (Cockcroft-Gault, see Appendix III);\n   7. Activated partial thromboplastin time (APTT) and international normalized ratio (INR) ≤1.5×ULN (patients on stable doses of anticoagulant therapy, such as low-molecular-weight heparin or warfarin, with INR within the therapeutic range of the anticoagulant, are eligible).\n9. Patients with hepatitis B virus (HBV) infection, as well as inactive\u002Fasymptomatic HBV carriers, or those with chronic or active HBV, will be allowed to enroll if HBV DNA \\\u003C500 IU\u002FmL (or 2500 copies\u002FmL) at screening. Patients who are positive for hepatitis C antibody will be allowed to enroll if HCV-RNA is negative at screening.\n10. Women of childbearing potential must have a negative urine or serum pregnancy test within ≤7 days before treatment. They must also agree to use an accepted method of contraception (e.g., intrauterine device, oral contraceptives, or condoms) during the study treatment period, as well as for at least 3 months after the last dose of PD-1 inhibitor and at least 6 months after the last dose of chemotherapy.\n11. Male subjects who have not been sterilized must agree to use an accepted method of contraception (e.g., intrauterine device, oral contraceptives, or condoms) during the study treatment period, as well as for at least 3 months after the last dose of PD-1 inhibitor and at least 6 months after the last dose of chemotherapy.\n\nExclusion Criteria:\n\n1. Patients who have been confirmed to have distant metastasis on imaging assessment before treatment.\n2. Patients who have previously received immune checkpoint inhibitor therapy.\n3. Patients who have previously received radiotherapy to the head and neck region.\n4. Patients who have had or currently have other malignancies (except for malignancies that have been cured and have been cancer-free for more than 5 years, such as basal cell carcinoma of the skin, cervical carcinoma in situ, and papillary thyroid cancer); if a patient has both hypopharyngeal cancer and esophageal cancer, and the esophageal lesion and hypopharyngeal lesion are anatomically non-adjacent, they should be diagnosed with multiple primary tumors and will not be eligible for enrollment.\n5. Uncontrolled cardiac symptoms or diseases, such as: a. NYHA Class II or higher heart failure; b. unstable angina; c. myocardial infarction within the past year; d. clinically significant supraventricular or ventricular arrhythmias that are not well controlled with medication.\n6. Patients who have received any of the following treatments:\n\n   1. Received any investigational drug within 4 weeks before the first dose of the study drug.\n   2. Enrolled in another clinical study concurrently, unless it is an observational (non-interventional) clinical study.\n   3. Require systemic treatment with corticosteroids (more than 10 mg prednisone equivalent per day) or other immunosuppressive agents within 2 weeks before the first dose of the study drug, except for corticosteroids used for local inflammation and prevention of allergies and nausea\u002Fvomiting. Other special circumstances should be discussed with the investigator. In the absence of active autoimmune disease, the use of inhaled or topical steroids and adrenal corticosteroid replacement at doses greater than 10 mg\u002Fday prednisone equivalent is permitted.\n   4. Received anti-tumor vaccines or live vaccines within 4 weeks before the first dose of the study drug (if the patient has received a COVID-19 vaccine, the interval between vaccination and treatment should be more than 2 weeks).\n   5. Underwent major surgery or had a severe injury within 4 weeks before the first dose of the study drug.\n7. Patients who have had a severe infection (CTCAE \\> Grade 2) within 4 weeks before the first dose of the study drug, such as severe pneumonia, bacteremia, or infectious complications requiring hospitalization; baseline chest imaging showing active pulmonary inflammation; symptoms and signs of infection within 4 weeks before the first dose of the study drug or requiring oral or intravenous antibiotic treatment.\n8. Patients with active autoimmune diseases or a history of autoimmune diseases (such as interstitial pneumonia, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases or syndromes); however, this does not include autoimmune hypothyroidism treated with a stable dose of thyroid hormone replacement therapy; type 1 diabetes treated with a stable dose of insulin; vitiligo or childhood asthma\u002Fallergies that have healed and do not require any intervention in adulthood.\n9. Patients with a history of immunodeficiency, including positive HIV test results, or those with other acquired or congenital immunodeficiency diseases, or a history of organ transplantation and allogeneic bone marrow transplantation.\n10. Patients with a history of interstitial lung disease (excluding radiation pneumonitis that has not been treated with corticosteroids) or non-infectious pneumonia.\n11. Patients with active tuberculosis infection identified through history or CT scan, or those with a history of active tuberculosis infection within 1 year before enrollment, or those with a history of active tuberculosis infection more than 1 year ago that was not properly treated.\n12. Patients with active hepatitis B (HBV DNA ≥500 IU\u002FmL or 2500 copies\u002FmL) or hepatitis C (positive hepatitis C antibody and HCV-RNA above the lower limit of detection of the assay).\n13. Patients with a known history of abuse of psychoactive drugs, alcoholism, or drug addiction.\n14. Pregnant or breastfeeding women.\n15. Patients who, in the investigator's judgment, have other factors that may force them to discontinue the study prematurely, such as having other serious diseases (including mental illnesses) requiring concurrent treatment, severely abnormal laboratory values, family or social factors, or conditions that may affect the patient's safety or the collection of trial data.","75 Years",{"count":112,"type":21},168,[114],"PHASE3","Neoadjuvant chemotherapy combined with immunotherapy has achieved promising pathological remission rates in locally advanced head and neck squamous cell carcinoma and has offered new hope for patients with locally advanced laryngeal and hypopharyngeal cancer. In our center's previous phase II study on locally advanced laryngeal and hypopharyngeal cancer, neoadjuvant chemotherapy combined with immunotherapy showed good 1 - year laryngeal preservation rate and 1 - year PFS rate. However, in locally advanced laryngeal and hypopharyngeal cancer, whether neoadjuvant chemotherapy combined with PD-1 inhibitor, compared with neoadjuvant chemotherapy, can improve laryngeal preservation survival, event - free survival and overall survival remains unclear.\n\nThus, this study aims to explore in locally advanced laryngeal and hypopharyngeal cancer whether neoadjuvant immuno - chemotherapy, compared with neoadjuvant chemotherapy, can improve laryngeal preservation survival and bring benefits in quality of life.",[26,117],"Hypopharyngeal Carcinoma",[119,120,121,122,123,124,125,126,127,128,129,130,131,132],"Neoadjuvant chemotherapy","Induction chemotherapy","Immunotherapy","anti-PD-1 antibody","PD-1 inhibitor","Tislelizumab","surgery","radiation","Locally advanced disease","Laryngeal preservation","Laryngeal cancer","Hypopharyngeal cancer","Head and neck cancer","Head and neck squamous cell carcinoma","2025-05-05",{"date":135,"type":37},"2025-05-08",{"date":137,"type":21},"2025-04-28",{"date":139,"type":21},"2031-05-01",{"name":141,"class":44},"Fudan University",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":17,"minAge":149,"maxAge":150,"enrollmentInfo":151,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":153,"conditions":154,"keywords":155,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":163,"leadSponsor":165,"locationsCount":72},"100580397","the-relationship-between-the-differential-expression-of-fosb-protein-in-laryngeal-cancer-tissues-and-clinical-prognosis-100580397","NCT06836765","The Relationship Between The Differential Expression Of FosB Protein In Laryngeal Cancer Tissues And Clinical Prognosis","Expression Of FosB Gene In Laryngeal Cancer Tissues And It's Clinical Prognosis Significance","Inclusion Criteria:\n\n* laryngeal squamous cell carcinoma was diagnosed ,and biopsy was confirmed by two pathologists;\n* Primary tumor of Laryngeal ,and there was no distant metastasis;\n* Standard treatment such as surgery and Preliminarily-diagnosed parients;\n* full clinical and pathological data information and good follow-up;\n* there was no previous fatal diseases such as complicated tumors.\n\nExclusion Criteria:\n\n* Secondary cancer or cancer with distant metastasis;\n* Patients who have not seen a doctor for the first time or have received surgery or radiotherapy or chemotherapy in other hospitals;\n* Clinical and pathological data were missing and loss to follow-up;\n* Patients who abandoned treatment or standard treatment procedures has not been completed;\n* The past medical history of other lethal diseases such as complicated tumors.","35 Years","90 Years",{"count":152,"type":21},100,"To determine whether there is statisstical difference in FosB (FBJ murine osteosarcoma viral oncogene homolog B) protein expression between laryngeal cancer tissue and adjacent tissue through immunohistochemistry methods.\n\nIf there are differences, further the investigators will collect relevant patients information,such as clinical stages, pathological types, clinical prognosis and so on. ultimately analyze whether it is related to the expression of FOsB in laryngeal cancer tissue and adjacent tissues",[26],[129,156,157,158],"FosB(FBJ murine osteosarcoma viral oncogene homolog B) gene","Immunohistochemistry","Cox regression analysis","2025-02-14",{"date":161,"type":37},"2025-02-20",{"date":98,"type":21},{"date":164,"type":21},"2025-05-01",{"name":166,"class":44},"Yang ji",{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":174,"enrollmentInfo":175,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":177,"conditions":178,"keywords":180,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":72},"100551720","ai-models-to-predict-thyroid-cartilage-invasion-in-laryngeal-carcinoma-100551720","NCT06463756","AI Models to Predict Thyroid Cartilage Invasion in Laryngeal Carcinoma","CT-based Radiomics, Two-dimensional and Three-dimensional Deep Learning Models to Predict Thyroid Cartilage Invasion in Laryngeal Carcinoma: a Multicenter Study","Inclusion Criteria:\n\n1. Availability of complete clinical data\n2. Surgery-proven or biopsy-proven diagnosis of laryngeal squamous cell carcinoma\n3. CT examination performed within 2 weeks before surgery\n\nExclusion Criteria:\n\n1. Patients who received preoperative chemotherapy or radiation therapy\n2. CT images with significant artifacts\n3. Patients with tumor recurrence","81 Years",{"count":176,"type":21},400,"This retrospective study was to develop and verify CT-based AI model to preoperatively predict the thyroid cartilage invasion of laryngeal cancer patients, so as to provide more accurate diagnosis and treatment basis for clinicians. In addition, the researchers investigated the prediction of survival outcomes of patients by the above optimal models.",[26,179],"Thyroid Cartilage",[181,182],"radiomics","deep learning","2024-08-20",{"date":185,"type":37},"2024-08-22",{"date":187,"type":37},"2023-08-13",{"date":189,"type":21},"2024-10-13",{"name":191,"class":44},"First Affiliated Hospital of Chongqing Medical University"]